Reframing Immune Design Beyond CD8+: Lessons from CD4+ T Cell Activation & Class II Antigen Presentation for Durable Tumor Control
Time: 10:30 am
day: Conference Day Two
Details:
• Evaluating tumor immune evasion via MHC-I downregulation and the implications for CD8+-centric PCV strategies
• Exploring novel methods to activate cytotoxic CD4+ T cells and target class II antigens to circumvent resistance and expand vaccine applicability beyond melanoma
• Applying foundational immunology and cell therapy insights to future-proof neoantigen vaccine design across solid tumors
• Framing CD4+-based responses not as an alternative, but as a complementary and underleveraged mechanism to broaden durable clinical benefit
